Genetic and molecular testing for solid organ transplantation — Coverage criteria
Customize your policy alerts
Sign up for all Community Health Plan Washington policy alerts
Know when Community Health Plan Washington releases new policies or updates existing guidance.
Monitor payer policy activity
Criteria and coding guidance for use of genetic and molecular laboratory tests (e.g., donor-derived cell-free DNA, gene expression panels, HLA typing) in the evaluation and management of solid organ transplant candidates and recipients.
A default coverage frequency of once every 12 months for serial dd-cfDNA testing in kidney and lung transplant recipients was adopted where guideline-specified frequency is not available.
Post-heart transplant gene expression panel criteria specify adult-only use (member must be age 18 years or older).
Replaced language stating tests were 'investigational' with wording that 'current evidence does not support' certain dd-cfDNA tests for lung transplant rejection for all indications.
For post-heart transplant tissue gene expression testing, the term 'for all indications' was added to the criteria set.
Coverage Criteria for Genetic and Molecular Tests in Transplantation
Donor-Derived Cell-free DNA for Heart Transplant Rejection
Covered when ALL of the following are met
ASTS/ISHLT guidance referenced; default annual coverage for routine monitoring
Post Heart Transplant Gene Expression Panels for Rejection Risk via Peripheral Blood
Covered when ALL of the following are met
Specific to adult low-risk patients per ISHLT 2023 guidance
Post Heart Transplant Gene Expression Panels for Rejection Risk via Tissue
Not covered / insufficient evidence
Test may improve discrimination between rejection types but is not routinely used or widely available
Donor-Derived Cell-free DNA for Kidney Transplant Rejection
Covered when ALL of the following are met
Specific listed clinical indications required
Evidence-Based Donor-Derived Cell-free DNA for Lung Transplant Rejection
Covered when ALL of the following are met
Distinguishes evidence-based (covered) assays from tests lacking established validity
HLA Typing for Transplantation
Covered when ALL of the following are met
Also covers donor evaluation and standard pre-transplant typing practices
dd-cfDNA testing — CMS MolDX intended uses — ONE-of intended uses by qualified physician
Covered when ONE of the following intended uses by a qualified physician is documented:
Per CMS MolDX LCD
Post-heart transplant peripheral blood gene expression panel (GEP) — coverage in adults per ISHLT
Covered in adults when meeting ISHLT guidance context
Per ISHLT 2023 guidance; recommendation limited to adults
Post-heart transplant tissue gene expression testing (MMDx) — clinical use / coverage stance
Clinical use
Clinical utility acknowledged but routine coverage not supported
HLA typing for transplantation — required/standard practice criteria
Required/standard practice
Per UpToDate, NMDP/ASTCT guidelines and OPTN requirements
Use of peripheral blood dd-cfDNA assays or peripheral blood gene expression panels for indications that are not explicitly listed in the organ-specific criteria (for example, routine surveillance outside the covered intervals, testing performed within 12 months of a prior dd-cfDNA test when that prior test is within the policy-specified interval, or other non‑listed purposes) is not supported by the evidence cited in this policy and may be denied. Documentation must demonstrate the member meets the organ-specific clinical criteria and timing requirements described in the coverage sections (e.g., age and post-transplant interval for AlloMap; clinical indications for kidney or lung dd-cfDNA) before coverage will be approved.
The sources cited in this policy and the referenced guidance do not describe or support routine post‑transplant HLA typing as a standard follow-up procedure. OPTN requirements specify HLA typing and reporting for candidates prior to waitlist registration and final crossmatch reporting before transplant, but the literature reviewed (including Tait et al.) contains no mention of performing HLA typing post‑transplant. Therefore routine post‑transplant HLA typing is not recommended by this policy unless a specific clinical indication exists and documentation supports medical necessity.
Molecular gene expression testing performed on allograft tissue (e.g., tissue‑based GEP/Molecular Microscope/MMDx) is not supported by current evidence for post‑heart transplant use for all indications. While tissue molecular assays may have investigational or selective clinical roles, the policy concludes that available evidence does not justify routine coverage of tissue‑based GEP for post‑heart transplant management.
Some dd‑cfDNA assays for lung transplant are categorized as having insufficient evidence of clinical validity or utility. Tests lacking independent technology assessments or professional society guideline support do not meet the policy’s threshold for coverage; the policy therefore states that current evidence does not support coverage of those dd‑cfDNA tests for lung transplant rejection for all indications.
Coding and Billing Examples
| 0055U | myTAIHEART (TAI Diagnostics) - example dd-cfDNA heart test |
| 0118U | Viracor TRAC dd-cfDNA - example |
| 0493U | Prospera (Natera) - example dd-cfDNA |
| 81479 | Unlisted molecular pathology procedure / lab (used in dd-cfDNA listings) |
| 81595 | AlloMap heart transplant gene expression panel |
| 0087U | Molecular Microscope MMDx - Heart |
| Z48.21 | Encounter for aftercare following heart transplant |
| Z94.1 | Heart transplant status |
| 0118U | Viracor cfDNA (Eurofins) - kidney dd-cfDNA example |
| 0493U | Prospera - kidney dd-cfDNA example |
| 0508U | VitaGraft Kidney Baseline + 1st Plasma Test |
| 0509U | VitaGraft Kidney Subsequent |
| 81479 | Unlisted molecular pathology procedure / lab |
| T86.11 | Complications of kidney transplant |
| T86.12 | Other complication of kidney transplant |
| Z94.0 | Kidney transplant status |
| MolDX L38582 | MolDX: Molecular Testing for Solid Organ Allograft Rejection (CMS LCD reference) |
Prior Authorization, Documentation, and Denial Triggers
Prior authorization / billing verification required
Prior authorization or verification of medical necessity is required and providers must confirm transplant type, timing since transplant, and clinical indication before billing listed transplant dd-cfDNA / molecular test codes.
- Verify transplant type (heart, kidney, lung) and that testing meets organ-specific coverage criteria before submitting codes (examples: 0055U, 0118U, 0493U, 0508U, 0509U, 81595, 0087U, 81479, 81370–81382).
- Obtain prior authorization or medical necessity verification per payer rules when billing these tests.
Surveillance frequency default and prior authorization
When serial dd-cfDNA surveillance is requested without an evidence-based guideline-specified regimen, coverage will default to once every 12 months and prior authorization may be required for more frequent surveillance.
- Default coverage frequency: once every 12 months for serial dd-cfDNA in the absence of clear guideline regimen.
- Requests for surveillance more frequent than 12 months should be submitted with prior authorization and supporting guideline or clinical rationale.
Monitoring frequency limitation — default 12 months
Coverage for routine monitoring is limited to a default interval of once every 12 months unless a specific, evidence-based guideline supports more frequent testing.
- Ensure prior dd-cfDNA testing was not performed within the prior 12 months to meet repeat-interval criteria for coverage.
- Provide guideline citation or evidence when requesting intervals shorter than 12 months.
Integrate dd-cfDNA with standard clinical assessments and biopsy
dd-cfDNA and other molecular test results must be interpreted alongside standard clinical assessments and, when appropriate, tissue biopsy results; these tests are intended to inform—not replace—comprehensive evaluation.
- Integrate dd-cfDNA findings with clinical signs, imaging, laboratory data, and biopsy results when available.
- Document how dd-cfDNA results influenced management decisions (e.g., decision to biopsy, change immunosuppression).
Required clinical documentation (transplant type, timing, prior testing, indication)
Documentation must include transplant type, timing since transplant, whether dd-cfDNA testing was performed within the prior 12 months, and the clinical indication prompting testing.
- Record transplant organ (heart, kidney, lung), date of transplant or interval since transplant.
- State clinical indication (e.g., clinical signs of acute rejection, inconclusive biopsy, monitoring immunosuppression).
- Note prior dd-cfDNA testing dates to confirm the 12-month repeat-interval requirement.
dd-cfDNA-specific clinical documentation required
When ordering dd-cfDNA, include physician-assessed intended use (one of the CMS MolDX LCD indications), affiliation with a transplant center, and the clinical context (e.g., suspicion of rejection, contraindication or inconclusive biopsy, or monitoring immunosuppression).
- Document which MolDX intended use applies: assist evaluation of immunosuppression adequacy; rule-out acute rejection to guide biopsy decisions; further evaluation after physician-assessed pretest; or assessment when biopsy is inconclusive/insufficient.
- Include evidence of transplant center affiliation or that ordering physician is working with a transplant program when applicable.
Denial triggers — requests outside specified indications or repeat interval
Requests for peripheral blood dd-cfDNA that do not meet the specified indications (for example, tests performed within the prior 12 months or for indications outside listed transplant types/uses) may be denied.
- Do not request dd-cfDNA for indications not listed in organ-specific criteria sets (coverage limited to specified clinical scenarios).
- Confirm the test has not been performed within the prior 12 months and that the clinical indication matches covered uses to avoid denial.
dd-cfDNA intended-use documentation required
Ordering dd-cfDNA without documenting a physician-assessed intended use consistent with the MolDX LCD (as listed) is not supported and may result in denial.
- Must document one of the MolDX intended uses: evaluation of immunosuppression adequacy in lieu of biopsy, rule-out test to guide biopsy, further evaluation after physician pretest, or assessment when biopsy is inconclusive.
- Provide the clinical rationale linking the intended use to the patient's management to meet coverage expectations.
Background and Definitions
This policy addresses use of peripheral blood and tissue genetic and molecular tests in solid organ transplantation. Covered services and requirements include peripheral blood donor‑derived cell‑free DNA (dd‑cfDNA) assays and peripheral blood gene expression panels (GEP) when used according to the organ‑specific criteria, as well as HLA typing for donor/recipient evaluation. Tissue‑based molecular testing is discussed separately and is generally considered not supported for routine post‑heart transplant use based on available evidence.
Pre-Transplant and Candidate Evaluation Criteria
HLA typing candidate indications
HLA typing indications
From HLA Typing section
Waitlist HLA reporting
Pre-transplant evaluation and listing requirements
Per OPTN requirements effective 10/31/2024; final crossmatch results must be reported before transplant for kidney and multi-organ transplants including kidney
Post-Transplant Coverage Limits and Conditions
Clinical Evaluation and Documentation Requirements
Evaluation documentation: transplant status, clinical context; kidney dd-cfDNA requires specific indication
Evaluation documentation must include the member's transplant status and clinical context; for kidney dd-cfDNA coverage, include one of the specified clinical indications (clinical signs of acute rejection, inconclusive biopsy, or monitoring of immunosuppression).
- Kidney dd-cfDNA coverage explicitly requires the test not have been performed in the previous 12 months and at least one listed clinical indication.
Physician-assessed pretest probability and documented intended use required per CMS MolDX
Physician-assessed pretest probability and documentation of the intended use are required to support dd-cfDNA testing in accordance with the CMS MolDX LCD (intended uses include assessing immunosuppression adequacy, rule-out AR, post-pretest evaluation, or inconclusive biopsy evaluation).
- MolDX requires the intended use to be one of the listed indications and implies documentation of clinical suspicion or pretest assessment.
Repeat: physician-assessed pretest and intended-use documentation required for dd-cfDNA
The policy reiterates that documentation supporting dd-cfDNA intended use must reflect a physician-assessed pretest and align with the MolDX LCD intended-use categories; lack of this documentation may jeopardize coverage.
- Intended-use categories include assessment of immunosuppression adequacy, rule-out AR, further evaluation after pretest, or assessment when biopsy is inconclusive.
Transplant Center Expectations
Transplant-center affiliation expected for ordering dd-cfDNA
Ordering dd-cfDNA tests is expected to be performed by physicians affiliated with a transplant center; transplant-center affiliation is referenced as an expectation for ordering these tests.
- CMS MolDX states tests "may be ordered by qualified physicians considering the diagnosis of AR affiliated with a transplant center."
Contraindications
Contraindications are not specified in the available document window.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.